NAUT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nautilus Biotechnology Inc (NAUT) does not present a strong buy opportunity at this time for a beginner investor with a long-term strategy. While there are positive indicators such as insider and hedge fund buying, the company's financial performance is weak, and the stock is currently experiencing a pre-market decline. The lack of significant news catalysts, weak financials, and no strong trading signals suggest holding off on investment for now.
The MACD is positive and contracting, indicating potential weakening momentum. RSI is neutral at 79.313, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 4.014 and 4.51, while support levels are at 2.409 and 1.914. However, the pre-market price is down 3.17%, showing short-term weakness.
Insiders and hedge funds are heavily buying the stock, with insider buying up 994.60% and hedge fund buying up 499900.00% over recent periods. Analysts have raised the price target to $4, citing improved fundamentals.
The company has no revenue growth, and net income and EPS have significantly declined YoY in the latest quarter. The pre-market price is down 3.17%, and historical stock trends suggest a likelihood of further short-term declines.
In Q4 2025, revenue remained at 0 with no growth YoY. Net income dropped to -$13.78M, down 21.67% YoY, and EPS declined to -0.11, down 21.43% YoY. Gross margin remains at 0.
Guggenheim raised the price target from $2.50 to $4 and maintained a Buy rating, citing improved fundamentals and a line of sight to modest revenue in 2027.
